Form 4/A for HCAT Health Catalyst, Inc.
Accepted 2022-04-08 00:00:00 ET · period of report 2022-03-09 · accession 0001562180-22-003346 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMA | 2022-04-08 | 2022-03-09 | HCAT | Horstmeier Paul | COO | M - OptEx | $15.84 | +4,687 | 201.0K | +2% | +$74.2K |
| DMA | 2022-04-08 | 2022-03-09 | HCAT | Horstmeier Paul | COO | S - Sale+OE | $25.33 | -20.7K | 180.3K | -10% | -$524.9K |
| DMA | 2022-04-08 | 2022-03-09 | HCAT | Horstmeier Paul | COO | M - OptEx | $0.00 | -4,687 | 6,248 | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-09 | M | A | 521 | $15.84 | 196,877 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-09 | M | A | 4,166 | $15.84 | 201,043 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-09 | S | D | 20,526 | $25.32 | 180,517 | D | — | — | (F2) Due to a technical and administrative error, the original Form 4, filed on March 11, 2022, incorrectly included the sale of 2,482 shares of Common Stock by the Reporting Person that did not occur and was duplicative of the sale of such 2,482 shares of Common Stock that were previously reported. (F3) Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $25.00 to $25.96, inclusive. |
| 4 | Common | Common Stock | 2022-03-09 | S | D | 201 | $26.02 | 180,316 | D | — | — | (F4) Represents the weighted average sale price of the shares sold ranging from $26.00 to $26.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) and (4). |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-03-09 | M | D | 4,166 | $0.00 | 39,569 | D | $15.84 · — to 2029-02-05 | 4,166 Common Stock | (F5) 25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-03-09 | M | D | 521 | $0.00 | 6,248 | D | $15.84 · — to 2029-02-05 | 521 Common Stock | (F6) 25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023. |